Scholars@Duke

In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d.

Publication ,  Journal Article
Greenblatt, LH
Published in: Ann Intern Med
January 2023
Published version (DOI) Link to item

Hsia J, Guthrie NL, Lupinacci P, et al. Randomized, controlled trial of a digital behavioral therapeutic application to improve glycemic control in adults with type 2 diabetes. Diabetes Care. 2022;45:2976-81. 36181554.

Duke Scholars

Lawrence Howard Greenblatt
Author Lawrence Howard Greenblatt Medicine, General Internal Medicine

Published In

Ann Intern Med

DOI

10.7326/J22-0109

EISSN

1539-3704

Publication Date

January 2023

Volume

176

Issue

1

Start / End Page

JC10

Location

United States

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Mobile Applications
  • Humans
  • General & Internal Medicine
  • Diabetes Mellitus, Type 2
  • Adult
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Greenblatt, L. H. (2023). In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d. Ann Intern Med, 176(1), JC10. https://doi.org/10.7326/J22-0109
Greenblatt, Lawrence H. “In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d.” Ann Intern Med 176, no. 1 (January 2023): JC10. https://doi.org/10.7326/J22-0109.
Greenblatt, Lawrence H. “In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d.” Ann Intern Med, vol. 176, no. 1, Jan. 2023, p. JC10. Pubmed, doi:10.7326/J22-0109.

Published In

Ann Intern Med

DOI

10.7326/J22-0109

EISSN

1539-3704

Publication Date

January 2023

Volume

176

Issue

1

Start / End Page

JC10

Location

United States

Related Subject Headings

  • Randomized Controlled Trials as Topic
  • Mobile Applications
  • Humans
  • General & Internal Medicine
  • Diabetes Mellitus, Type 2
  • Adult
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences